SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals informs about communication on TDS

25 Aug 2022 Evaluate

SMS Pharmaceuticals has informed that the Company has sent a detailed communication on 24th August, 2022 to all the Shareholders, whose email IDs are registered with the Company/Depositories, indicating information regarding deduction of Income Tax at source on dividend and the process and documentation required for claiming exemption from deduction / withholding of tax on dividends. A specimen copy of the said communication sent to the shareholders is enclosed. This communication is also being made available on the website of the Company www.smspharma.com at Investors Section.

The above information is a part of company’s filings submitted to BSE.

SMS Pharmaceuticals Share Price

427.60 3.45 (0.81%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×